CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.
| 0.041 | |
| 0.0393 | |
| - | |
| 0.0436 | |
| 0.035 | |
| 0.003-0.1 | |
| 2 189 K | |
| 50 197 K | |
| 0 | |
| -0.0012 | |
| 0.605 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Hamilton, Ontario, July 19, 2019 (GLOBE NEWSWIRE) -- CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC:CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery syst...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
